According to a new report by Polaris Market Research, the global rare disease genetic testing market was valued at USD 1,242.8 million in 2025 and is projected to reach USD 3,790.38 million by 2034, expanding at a CAGR of 13.20% over the forecast period. Growth is underpinned by rising demand for early disease detection, expanding adoption of personalized medicine, and accelerating use of next-generation sequencing (NGS) across key end-use settings.

What Is Driving Rare Disease Genetic Testing Market Growth?

Demand is climbing as growing emphasis on early diagnosis converges with the shift toward personalized, genetics-based treatment planning. Clinicians and diagnostic providers are prioritizing molecular-level insight, pushing rare disease genetic testing adoption across hospitals, diagnostic laboratories, and research institutions worldwide. Polaris analysts note that falling sequencing costs and expanding NGS gene-panel availability position the market for sustained double-digit growth through 2034, with North America emerging as the largest revenue contributor and Asia Pacific posting the fastest incremental gains.

Key Trends Shaping the Rare Disease Genetic Testing Industry

AI-Enabled Variant Interpretation

Artificial intelligence is increasingly embedded in genetic testing workflows, helping laboratories classify variants faster and interpret complex genomic datasets with greater accuracy. AI-assisted tools are shortening diagnostic turnaround times and supporting more precise disease-risk prediction, a technology advancement that is reshaping how rare disease genetic testing is delivered.

Evolving Regulatory Landscape

Oversight frameworks such as the U.S. FDA and CLIA requirements, the EU's In Vitro Diagnostic Regulation, and national health authority pathways across Asia Pacific are shaping test validation, laboratory certification, and market entry timelines. Providers that align early with regional compliance requirements are better positioned to scale, making the regulatory landscape a defining feature of near-term market outlook.

Falling Sequencing Costs and Rising Investment

Declining whole genome and whole exome sequencing costs are widening patient access, while continued R&D investment and strategic collaborations among diagnostics companies, biotechs, and research institutions are accelerating gene discovery. This competitive landscape of partnerships and platform upgrades is a core driver of the market's long-term growth outlook.

Market Segmentation: Breaking Down the Rare Disease Genetic Testing Market

Polaris segments the rare disease genetic testing market by technology, speciality, disease type, end use, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Technology

The next-generation sequencing (NGS) segment led the market in 2025, accounting for 38.7% of revenue, on the strength of its broad adoption across cancer, neurological, cardiovascular, pediatric, and psychiatric diagnostics. Array technology, PCR-based testing, FISH, Sanger sequencing, and karyotyping round out the technology mix, with NGS-based gene panels continuing to expand as sequencing platforms improve in speed and accuracy.

By Speciality

Molecular genetic tests remain the dominant speciality, driven by rising adoption of advanced diagnostic techniques and precision medicine. Chromosomal genetic tests are gaining share as cytogenetic technologies advance and the prevalence of chromosomal disorders increases, signaling where near-term demand — and search intent around "chromosomal genetic testing" — is shifting.

By End Use

Among end-use settings, hospitals and clinics remain a leading point of care, while diagnostic laboratories are projected to post the strongest incremental growth, expanding at a CAGR of 13.8% through the forecast period as sequencing technology advances and demand for precise, early detection grows.

By Disease Type

On a disease-type basis, oncology applications hold significant weight in overall demand given the role of genetic testing in identifying tumor-driving mutations, while neurological and metabolic disease categories are expected to see strengthening incremental growth as targeted-therapy pipelines expand and screening programs broaden.

Regional Outlook: Where Is Rare Disease Genetic Testing Growing Fastest?

North America led the market in 2025 on the back of advanced healthcare infrastructure, strong government support, and extensive regulatory approvals for new genetic tests, while Asia Pacific is expected to post the fastest CAGR of 14.2% through 2034, driven by rising healthcare investment. Within North America, the United States remains the largest single market, supported by initiatives such as the All of Us Research Program; within Asia Pacific, expanding genomic research infrastructure across China, Japan, and India is the primary growth engine. Europe rounds out the top three, supported by rising R&D activity, government-backed cancer-screening initiatives, and growing clinical trial volume in markets such as the UK.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/rare-disease-genetic-testing-market 

Competitive Landscape: Leading Rare Disease Genetic Testing Companies

Key players profiled in the report include Centogene N.V., 3billion Inc., GeneDx LLC, and Invitae Corporation, who are focusing on product innovation, strategic partnerships, and R&D investment to strengthen market position across the NGS and molecular genetic testing segments outlined above. Recent moves include GeneDx's March 2026 genetic testing collaboration with Zevra Therapeutics to support patients with suspected Niemann-Pick Disease Type C, and Regeneron's completed USD 256 million acquisition of 23andMe in March 2025, both aimed at deepening genomic data reach and testing capabilities across North America.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the rare disease genetic testing market forecast, this report benchmarks market share, segment-level pricing, and forecast data — by technology, speciality, disease type, end use, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking oncology-linked genetic testing as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

Gas Delivery Systems Market

Diet and Nutrition Apps Market

Advanced Glass Market

Pad-mounted Switchgear Market

Diet and Nutrition Apps Market

Solar Panels Market

Lidar Drone Market

Fire Trucks Market: A Progressive Vehicle for Assisting Sufferers in Calamities

U.S. Premium Bottled Water Market